Stocktoria
INTERPACE BIOSCIENCES, INC. IDXG
INTERPACE BIOSCIENCES, INC. (IDXG) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $38.7M at a 63.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: 1.99 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1961 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.142 |
| Retained earnings / assets | -6.23 |
| EBIT / assets | 0.121 |
| Equity / liabilities | 1.949 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IDXG | INTERPACE BIOSCIENCES, INC. | 4/9 | -16.52 | 1.9 | -17.5% |
| UTMD | UTAH MEDICAL PRODUCTS INC | 3/9 | — | — | -5.8% |
| CTSO | Cytosorbents Corp | 3/9 | — | — | +4.1% |
| KRMD | KORU Medical Systems, Inc. | 4/9 | -0.06 | — | +22.2% |
| SSII | SS Innovations International, Inc. | 4/9 | -0.09 | — | +105.7% |
| OBIO | Orchestra BioMed Holdings, Inc. | 5/9 | -7.02 | — | — |
| SNWV | SANUWAVE Health, Inc. | 6/9 | -19.06 | 6.3 | +35% |
About INTERPACE BIOSCIENCES, INC.
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
FAQ
Is IDXG financially healthy?
INTERPACE BIOSCIENCES, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does IDXG pay a dividend?
No, INTERPACE BIOSCIENCES, INC. does not currently pay a dividend.
How profitable is IDXG?
In FY2025, INTERPACE BIOSCIENCES, INC. had a net margin of 63.5% and a return on equity of 109.9%.
What is IDXG's P/E ratio?
INTERPACE BIOSCIENCES, INC.'s trailing price-to-earnings (P/E) ratio is about 1.9×, based on its latest annual earnings.
Is IDXG a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on INTERPACE BIOSCIENCES, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a P/E of about 1.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.